慢性骨髓增殖性肿瘤患者的年龄相关性黄斑变性
这项基于丹麦全国登记数据的队列研究纳入7958例骨髓增殖性肿瘤(MPN)患者及77445名年龄性别匹配对照,比较年龄相关性黄斑变性(AMD)风险。MPN患者AMD发病率为每1000人年5.2,对照组为4.3;校正后风险比1.3(95%CI 1.1-1.5),新生血管性AMD风险比1.4(95%CI 1.2-1.6)。结果提示MPN患者AMD风险增加,支持系统性炎症可能参与AMD发病。
要点
- MPN患者AMD发病率每1000人年5.2,对照组4.3,校正后HR 1.3(95%CI 1.1-1.5)。
- 真性红细胞增多症患者AMD风险HR 1.4(95%CI 1.2-1.7),原发性血小板增多症HR 1.2(95%CI 1.0-1.6)。
- MPN患者新生血管性AMD风险HR 1.4(95%CI 1.2-1.6)。
核心结论
- 研究结果提示MPN患者AMD风险增加,支持系统性炎症可能参与AMD发病机制。
研究设计与样本
- 全国性人群队列研究,使用丹麦登记数据,纳入1994年1月1日至2013年12月31日诊断为原发性血小板增多症、真性红细胞增多症、骨髓纤维化或不能分类MPN的全部患者。
- 每例患者匹配10名年龄和性别匹配的对照,共纳入7958例MPN患者和77445名对照。
- 所有既往无AMD者从诊断日期(对照为对应入组日期)随访至首次AMD诊断、死亡或移民、或2013年12月31日,以先发生者为准。
主要发现
- MPN患者AMD发病率为每1000人年5.2(95%CI 4.6-5.9),对照组为4.3(95%CI 4.1-4.4)。
- MPN患者10年AMD风险为2.4%(95%CI 2.1%-2.8%),对照组为2.3%(95%CI 2.2%-2.4%)。
- MPN患者AMD总体风险增加,校正后HR 1.3(95%CI 1.1-1.5)。
- 各亚型校正后HR:原发性血小板增多症1.2(95%CI 1.0-1.6),真性红细胞增多症1.4(95%CI 1.2-1.7),骨髓纤维化1.7(95%CI 0.8-4.0),不能分类MPN 1.5(95%CI 1.1-2.1)。
- MPN患者新生血管性AMD风险较高,校正后HR 1.4(95%CI 1.2-1.6)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It has been suggested that systemic inflammation increases the risk of age-related macular degeneration (AMD). Given that chronic immune modulation is present in patients with myeloproliferative neoplasms (MPNs), the risk of AMD in these patients may be increased. OBJECTIVE: To compare the risk of AMD in patients with MPNs with the risk of AMD in matched controls from the general population. DESIGN, SETTING, AND PARTICIPANTS: A nationwide population-based cohort study using Danish registers was conducted of all patients in Denmark who received a diagnosis between January 1, 1994, and December 31, 2013, of essential thrombocythemia, polycythemia vera, myelofibrosis, or unclassifiable MPNs. For each patient, 10 age- and sex-matched controls were included. All patients without prior AMD were followed up from the date of diagnosis (or corresponding entry date for the controls) until the first AMD diagnosis, death or emigration, or December 31, 2013, whichever occurred first. Data analysis was performed from April 1, 2015, to October 31, 2016. MAIN OUTCOMES AND MEASURES: Incidence of AMD recorded in specialized hospital-based care. The rates and absolute risk of AMD were calculated. Using Cox proportional hazards regression models, smoking and risk-time adjusted hazard ratios (HRs) between patients and controls were calculated. In addition, HRs of neovascular AMD after 2006 were calculated since antivascular endothelial growth factor treatment was introduced nationwide at hospitals thereafter. RESULTS: A total of 7958 patients with MPNs (4279 women [53.8%] and 3679 men [46.2%]; mean [SD] age at diagnosis, 66.4 [14.3] years) were included in the study. The rate of AMD per 1000 person-years at risk was 5.2 (95% CI, 4.6-5.9) for patients with MPNs (2628 with essential thrombocythemia, 3063 with polycythemia vera, 547 with myelofibrosis, and 1720 with unclassifiable MPNs) and 4.3 (95% CI, 4.1-4.4) for the 77 445 controls, while the 10-year risk of AMD was 2.4% (95% CI, 2.1%-2.8%) for patients with MPNs and 2.3% (95% CI, 2.2%-2.4%) for the controls. The risk of AMD was increased overall for patients with MPNs (adjusted HR, 1.3; 95% CI, 1.1-1.5), with adjusted HRs for the subtypes of 1.2 (95% CI, 1.0-1.6) for essential thrombocythemia, 1.4 (95% CI, 1.2-1.7) for polycythemia vera, 1.7 (95% CI, 0.8-4.0) for myelofibrosis, and 1.5 (95% CI, 1.1-2.1) for unclassifiable MPNs. In addition, patients with MPNs had a higher risk of neovascular AMD (adjusted HR, 1.4; 95% CI, 1.2-1.6). CONCLUSIONS AND RELEVANCE: Our results suggest that patients with MPNs are at increased risk of AMD, supporting the possibility that systemic inflammation is involved in the pathogenesis of AMD.
引用
- Bak M, Sørensen TL, Flachs EM, et al. Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms. JAMA Ophthalmol. 2017. PMID: 28655032. doi:10.1001/jamaophthalmol.2017.2011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。